A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Phase of Trial: Phase II
Latest Information Update: 06 May 2017
At a glance
- Drugs Vamorolone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors ReveraGen BioPharma
- 07 Jun 2017 Biomarkers information updated
- 28 Jun 2016 Status changed from not yet recruiting to recruiting.
- 07 Jun 2016 Drug dose for drug Vamorolone has been changed in each arm mentioned in treatment table.